Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 11INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 13Other solid neoplasm 6Head & Neck 4Breast 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

Rituximab 377Cyclophosphamide 180Bendamustine Hydrochloride 110obinutuzumab 100Vincristine 95fludarabine 92Prednisone 90Doxorubicin 90ibrutinib 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24Prednisolone 23tositumomab I-131 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × Lymphoid × Clear all
NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
75 enrolled 10 charts
Lymphoid

Hodgkin Disease

NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
97 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡